Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APP | P05067 | 5/20 | 0.58 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | BCHE | P06276 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | F2 | P00734 | 1/20 | 0.55 |
| ▸ | PPARA | Q07869 | 1/20 | 0.54 |
| ▸ | MAOB | P27338 | 1/20 | 0.53 |
| ▸ | NPC1 | O15118 | 2/20 | 0.52 |
| ▸ | RAB9A | P51151 | 1/20 | 0.52 |
| ▸ | VNN1 | O95497 | 1/20 | 0.52 |
| ▸ | CLK1 | P49759 | 1/20 | 0.51 |
| ▸ | CLK2 | P49760 | 1/20 | 0.51 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.51 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.51 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5622343 | 0.92 | VNN1 (0.59) | APPMEN1KMT2ANPC1RAB9A | |
| SCHEMBL14075904 | 0.87 | F2 (0.70) | MEN1BCHEKMT2AF2 | |
| SCHEMBL10055052 | 0.85 | F2 (0.63) | APPMEN1BCHEKMT2AF2 | |
| SCHEMBL10055054 | 0.82 | MEN1 (0.50) | MEN1KMT2AF2NPC1RAB9A | |
| SCHEMBL20000873 | 0.79 | APP (0.80) | APPMEN1BCHEKMT2AMAOB | |
| Msx-122 SCHEMBL10054965 | 0.77 | CXCR4 (0.61) | MEN1KMT2ANPC1RAB9A | |
| SCHEMBL27429524 | 0.77 | VNN1 (0.61) | MEN1KMT2ANPC1RAB9AVNN1 | |
| SCHEMBL31080534 | 0.76 | NPC1 (0.61) | APPMAOBNPC1RAB9ACLK4 | |
| SCHEMBL28366776 | 0.76 | APP (0.65) | APPF2MAOBNPC1RAB9A | |
| SCHEMBL2312890 | 0.76 | CXCR4 (0.74) | KMT2AF2NPC1RAB9ADYRK1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080227799-A1 | CXCR4 Antagonists Including Heteroatoms for the Treatment of Medical Disorders | LIOTTA DENNIS C | 2008-09-18 | — | — | US | disclosed |
| US-20080227799-A1 | CXCR4 Antagonists Including Heteroatoms for the Treatment of Medical Disorders | LIOTTA DENNIS C | 2008-09-18 | — | — | US | disclosed |
| WO-2008008852-A2 | CXCR4 ANTAGONISTS INCLUDING HETEROATOMS FOR THE TREATMENT OF MEDICAL DISORDERS | EMORY UNIVERSITY (US) | 2008-01-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080227799-A1 | CXCR4 Antagonists Including Heteroatoms for the Treatment of Medical Disorders | CXCL12, CXCR4, CXCR1 | APP 4065/4885MEN1 3076/4885BCHE 4819/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.